Recent investigations have centered on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopamine communication. While GLP activators are increasingly employed for addressing type 2 T2DM, their potential consequences on reward circuits,